<DOC>
	<DOCNO>NCT00994929</DOCNO>
	<brief_summary>The purpose study determine biologic efficacy safety rhIL-11 give subcutaneously adults moderate mild hemophilia A Von Willebrand disease unresponsive DDAVP . Biologic efficacy measure number percent increase VWD coagulation test ( FVIII : C , VWF : Ag , VWF : RCo , closure time , APTT , VWF multimers ) normal range , least 1.5-3 time baseline , follow dose rhIL-11 give daily 4 day , boost DDAVP infusion day 4 , DDAVP contraindicate . Safety measure frequency adverse event , include fever , headache , fatigue , myalgia , arthralgia , fluid retention , edema .</brief_summary>
	<brief_title>Efficacy Safety IL-11 DDAVP Unresponsive</brief_title>
	<detailed_description>This prospective , single center , Phase II biologic effect study recombinant interleukin-11 ( rhIL-11 , Neumega ) subject hemophilia A , moderate mild ; Von Willebrand disease unable take desmopressin acetate ( DDAVP ) unresponsive , allergic , DDAVP contraindicate . The purpose study establish biologic efficacy safety rhIL-11 able take DDAVP . Study subject include adult , age &gt; = 18 year , hemophilia A , moderate , define factor VIII 0.01-0.04 U/ml , mild , define factor VIII &gt; = 0.05 U/ml ; VWD define low VWF : RCo /or low VWF : Ag , past bleed history , and/or family history VWD . A total 10-16 subject enrol order assure 10 complete study . The specific aim study : 1 ) determine biologic effect rhIL-11 give 4 consecutive day ; 2 ) determine safety rhIL-11 use subject hemophilia A , moderate mild ; VWD unresponsive unable take DDAVP ; 3 ) determine mechanism hemostatic effect rhIL-11 . The biologic efficacy outcome measure VWD-related coagulation test ( VWF : RCo , FVIII : C , VWF : Ag , closure time ) rhIL-11 injection . Safety outcomes measure number frequency adverse event , include fever , headache , fatigue , myalgia , arthralgia , fluid retention , edema . The mechanism rhIL-11 hemostatic effect measure VWFmRNA rhIL-11 response . Response DDAVP follow rhIL-11 also assess DDAVP contraindicate . The study last 1 month per subject , 24 month entire study .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Males female &gt; = 18 year age . A diagnosis hemophilia A , moderate ( FVIII : C 0.010.04 U/ml ) mild ( FVIII : C &gt; = 0.05 U/ml ) ; diagnosis VWD , define low VWF : RCo past bleed history . For VWD , inability use DDAVP due ) unresponsiveness define VWF : RCo FVIII : C level lower 50 IU/dl less 3fold increase 0.3 microgram/kg DDAVP ; ii ) allergic reaction seizures ; iii ) contraindication DDAVP . Willingness blood drawn . Willingness sign inform consent . Presence bleed disorder , acquire Von Willebrand disease , primary thrombocytopenia . Use immunomodulatory experimental drug , diuretic . Pregnant lactating woman . Previous cardiac disease , congestive failure , arrhythmia ( e.g . atrial fibrillation , atrial flutter ) , hypertension , MI , stroke , thrombosis . Past allergic reaction Neumega . Surgery within past 8 week . Inability comply study protocol requirement . Concomitant use antiplatelet drug , anticoagulant , dextran , aspirin NSAIDs . Treatment DDAVP , cryoprecipitate , whole blood , plasma plasma derivative contain substantial quantity FVIII and/or VWF within five day study . Baseline safety and/or hematology lab value outside normal limit and/or EKG indicate arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>biologic effect</keyword>
	<keyword>von Willebrand disease</keyword>
	<keyword>hemophilia</keyword>
	<keyword>interleukin-11</keyword>
	<keyword>DDAVp</keyword>
</DOC>